⚠ Evidence warning: Clinical trials or other evidence do not support the claim that a successful transplant fully resolves the classic triad and eliminates the risk of lymphoma. This page keeps it as a report of what people, websites or other media say.
Wiskott-Aldrich Syndrome (WAS)
- Overview
- The Classic Triad
- Disease Spectrum
- Complications
- Laboratory Findings
- Diagnosis
- Treatment
- Prognosis
- Key Research Papers
- Connections
Overview
Wiskott-Aldrich Syndrome (WAS) is a rare X-linked primary immunodeficiency disorder characterized by profound immune dysregulation combined with thrombocytopenia (low platelet count with abnormally small platelets). It arises from loss-of-function mutations in the WAS gene located on chromosome Xp11.23, which encodes the Wiskott-Aldrich Syndrome protein (WASp). Because inheritance is X-linked, the disorder affects almost exclusively males, with an incidence given in a 2014 review as approximately one to four cases per 1,000,000 live male births.
WASp is a cytoskeletal regulator expressed exclusively in hematopoietic cells. It acts as a molecular scaffold that links upstream signaling — particularly the small Rho GTPase CDC42 — to downstream actin polymerization via the Arp2/3 complex. When WASp is absent or non-functional, multiple immune-cell lineages fail to perform actin-dependent processes:
- T cells: Impaired immunological synapse formation, reduced activation and cytokine production.
- Natural killer (NK) cells: Defective lytic granule polarization, reduced cytotoxicity against infected and tumor cells.
- B cells: Abnormal antigen-receptor signaling, poor class switching, especially to immunoglobulin M (IgM) → immunoglobulin G (IgG) for polysaccharide antigens.
- Regulatory T cells (Tregs): Reduced numbers and function, leading to paradoxical autoimmunity despite immunodeficiency.
- Platelets: Disordered megakaryocyte cytoskeletal dynamics producing characteristically small, fragile platelets (microplatelets) with accelerated peripheral destruction.
- Dendritic cells and macrophages: Impaired phagocytosis and antigen presentation.
The result is a combined B-cell and T-cell immunodeficiency superimposed on bleeding risk, with a significant propensity for autoimmune disease and malignancy in untreated or undertreated patients.
The Classic Triad
The hallmark of classic Wiskott-Aldrich Syndrome is the simultaneous occurrence of three clinical features that together strongly suggest the diagnosis. Their absence does not rule it out: in a survey of 154 patients, the full classic triad (low platelets with small platelets, recurrent ear infections and eczema) was seen in only 27%, 5% had only infections and 20% had only blood findings before diagnosis, and the authors concluded that many patients have an atypical presentation and often need a panel of tests.
1. Thrombocytopenia with Microplatelets
The platelet abnormality in WAS is unique and diagnostically important. Unlike immune thrombocytopenic purpura (ITP), where the immune system destroys normal or large platelets, in WAS the platelets are intrinsically abnormal — they are small (low mean platelet volume, MPV) as well as reduced in number. Platelet counts typically range from 20,000 to 50,000/µL (normal 150,000–400,000/µL). The low MPV is a key distinguishing laboratory feature from ITP, where MPV is normal or elevated.
Bleeding manifestations include:
- Petechiae and purpura, often apparent in the first weeks of life.
- Bloody diarrhea in infants — a presenting sign that can be mistaken for cow's-milk allergy or inflammatory bowel disease.
- Prolonged bleeding from minor wounds.
- Intracranial hemorrhage (ICH) — the most feared acute complication and historically the leading cause of death in young WAS patients.
2. Eczema
Atopic dermatitis in WAS is often severe and begins in early infancy, frequently as the first or most prominent feature. The eczema can be indistinguishable from severe atopic dermatitis of other causes but is characteristically refractory to standard topical therapies and prone to superinfection, particularly with Staphylococcus aureus and Herpes simplex virus, which causes the widespread skin infection called eczema herpeticum. It is driven by dysregulated Th2 skewing and elevated immunoglobulin E (IgE), reflecting the underlying immune imbalance.
3. Recurrent Infections
WAS produces a combined humoral and cellular immunodeficiency. The antibody deficiency is selective but clinically significant — patients have a characteristically poor response to T-independent type 2 antigens (polysaccharide capsule components), making them uniquely vulnerable to encapsulated organisms:
- Streptococcus pneumoniae (pneumonia, bacteremia, meningitis)
- Haemophilus influenzae type b (meningitis, epiglottitis)
- Neisseria meningitidis (meningococcemia)
Viral susceptibility is also elevated, particularly to herpesviruses:
- Cytomegalovirus (CMV) — disseminated disease
- Epstein-Barr virus (EBV) — reactivation, lymphoproliferation
- Herpes simplex virus (HSV) — eczema herpeticum
- Varicella-zoster virus (VZV) — severe or disseminated chickenpox
Opportunistic infections (Pneumocystis jirovecii pneumonia, fungal infections) occur particularly in patients with severe WASp deficiency.
Disease Spectrum
WAS is not a single uniform phenotype. Depending on the nature of the WAS gene mutation and residual WASp function, the clinical picture spans a wide spectrum. A clinical severity score (WAS score 1–5) is widely used:
- Score 1–2 — X-Linked Thrombocytopenia (XLT): The mildest end of the spectrum. Patients have thrombocytopenia with small platelets but minimal or no eczema and only mild, recurrent (not severe) infections. WASp is partially functional. Many XLT patients are diagnosed incidentally or after a bleeding event in childhood. Near-normal lifespan is possible with supportive care, but complications are common: among 173 patients with this form in a 12-country study, serious bleeding occurred in 13.9%, life-threatening infections in 6.9%, autoimmunity in 12.1% and malignancy in 5.2%, and a 2014 review of registry data gives event-free survival of 74% at 15 years and 56% by 30 years.
- Score 3–4 — Classic WAS: The full triad of thrombocytopenia, eczema, and recurrent combined infections. WASp is absent or severely reduced. Without hematopoietic stem cell transplantation (HSCT), prognosis is poor.
- Score 5 — Severe WAS with autoimmunity or malignancy: WASp-null state with paradoxical autoimmune disease arising from regulatory T cell (Treg) dysfunction. These patients suffer from both immunodeficiency and immune-mediated tissue damage simultaneously.
A 2025 expert review recommends discontinuing the term X-linked thrombocytopenia “as it implies a mild and uncomplicated disease, which is not the norm”, and describing each patient by genetic profile, disease severity and clinical course instead.
Female Carriers
Female carriers of WAS mutations are typically asymptomatic due to preferential X-inactivation that silences the mutant allele in hematopoietic cells. However, in carriers with unfavorable (non-skewed) X-inactivation, mild thrombocytopenia may occur. Rarely, a female with Turner syndrome (45,X) or compound heterozygosity can be fully affected.
X-Linked Neutropenia (XLN)
A distinct gain-of-function mutation in the GBD domain of WAS (L270P and I294T alleles) causes X-linked neutropenia with myelodysplasia, without thrombocytopenia — the opposite end of the WASp dysfunction spectrum. This underscores the role of WASp in myeloid lineage regulation beyond just immune cells and platelets.
Complications
Untreated or undertreated Wiskott-Aldrich Syndrome carries four major categories of life-threatening or debilitating complications:
Bleeding
Intracranial hemorrhage (ICH) is the most feared acute complication and was historically the most common cause of early death. Even minor head trauma can precipitate ICH in a child with a platelet count of 20,000–30,000/µL. Gastrointestinal bleeding, epistaxis, and bleeding after dental procedures or surgery are also significant risks throughout life.
Infections
Severe, recurrent bacterial infections — particularly meningitis and bacteremia from encapsulated organisms — were the second major cause of death in the pre-IVIG and pre-HSCT era. Opportunistic infections (Pneumocystis pneumonia, cryptococcal meningitis, disseminated cytomegalovirus) occur in patients with significant T-cell dysfunction. Epstein-Barr virus-driven lymphoproliferative disease bridges the infection and malignancy categories.
Malignancy
WAS patients face a 20- to 22-fold increased risk of malignancy compared with the general population. The vast majority are lymphomas, predominantly Epstein-Barr virus-driven non-Hodgkin B-cell lymphomas (Burkitt-like, diffuse large B-cell). Leukemia and other hematologic malignancies also occur. Malignancy can begin in childhood: a survey reported in a 2014 review found that 13% of patients developed malignancy at a mean age of 9.5 years. Its risk is described as substantially eliminated by successful HSCT, although the same review estimates malignancy after transplant at 3.3% in WAS.
Autoimmunity (Paradoxical)
Approximately 40% of WAS patients develop significant autoimmune disease — a counterintuitive finding given the underlying immunodeficiency. The mechanism is Treg dysfunction: WASp-deficient regulatory T cells fail to adequately suppress autoreactive clones. Manifestations include:
- Autoimmune hemolytic anemia (AIHA) — most common autoimmune complication
- Vasculitis (including cerebral vasculitis)
- Immune nephritis
- Inflammatory bowel disease-like enteropathy
- Arthritis
- Autoimmune cytopenias
The coexistence of autoimmunity worsens prognosis and increases the urgency of definitive HSCT.
Laboratory Findings
The laboratory profile of WAS is distinctive and, when the full pattern is recognized, strongly supports the diagnosis before molecular confirmation:
- Thrombocytopenia with low MPV (microplatelets): This combination — low platelet count AND low mean platelet volume — is the diagnostic hallmark. In ITP, platelets are large (high MPV) because the bone marrow compensates by releasing immature, large platelets. In WAS, the platelets are intrinsically small due to the cytoskeletal defect in megakaryocytes.
- Low immunoglobulin M: Often markedly reduced; polysaccharide-specific immunoglobulin M responses are disproportionately impaired.
- Low to normal immunoglobulin A (IgA): Reduced in many patients.
- Normal or elevated immunoglobulin G and immunoglobulin E: immunoglobulin G may be normal or low depending on disease severity; immunoglobulin E is often elevated, reflecting Th2 skewing and eczema.
- Poor vaccine responses: Impaired antibody responses to T-independent polysaccharide vaccines (pneumococcal polysaccharide, unconjugated Haemophilus influenzae type b) — a functional test distinguishing WAS from simple quantitative antibody deficiencies.
- Impaired natural killer cell cytotoxicity: Measurable by chromium-release assay; reflects WASp's critical role in lytic granule polarization.
- Reduced or absent WASp protein by intracellular flow cytometry: This is the first-line confirmatory test after clinical suspicion. Intracellular staining of peripheral blood mononuclear cells (PBMCs) using an anti-WASp antibody rapidly identifies absent or severely reduced WASp expression.
- WAS gene sequencing: Definitive molecular confirmation. Over 300 distinct mutations have been identified (missense, nonsense, splice-site, small insertions/deletions). Genotype-phenotype correlation exists but is imperfect.
- Lymphocyte subsets: T- and B-cell counts are often normal in early childhood but progressive T-cell lymphopenia develops over time, particularly CD8+ T cells. Natural killer cells are present but functionally impaired.
Diagnosis
The diagnosis of WAS comes into question in any male infant or child presenting with:
- Thrombocytopenia with small platelets (low MPV) — especially if present from birth or early infancy
- Bloody diarrhea in infancy (often misattributed to cow's-milk protein allergy)
- Severe or recurrent infections disproportionate to age
- Severe atopic eczema unresponsive to standard therapy
- Any combination of the above classic triad features
Stepwise Diagnostic Approach
- Complete blood count (CBC) with differential and smear: Confirms the low platelet count and shows platelet size and shape. Automated MPV is the fastest clue — a low MPV in a male with a low platelet count raises strong suspicion of WAS.
- Immunoglobulin quantification: immunoglobulin G, immunoglobulin A, immunoglobulin M, immunoglobulin E levels.
- Vaccine antibody titers: Responses to both protein (tetanus, diphtheria) and polysaccharide (pneumococcal) antigens are measured; selective polysaccharide unresponsiveness is highly characteristic.
- WASp protein expression by intracellular flow cytometry: The pivotal screening test. Absent or markedly reduced WASp in PBMCs confirms significant WAS gene dysfunction. A small percentage of patients with missense mutations produce a non-functional but detectable WASp; flow cytometry may be normal or near-normal in these cases.
- WAS gene sequencing: Definitive confirmation and guides family counseling and prenatal testing. Next-generation sequencing panels covering the full coding sequence and splice sites are available in most reference laboratories.
Differential Diagnosis
- Immune thrombocytopenic purpura (ITP): Platelets are large (high MPV), no eczema, no recurrent infections, normal immunoglobulins. The most common initial misdiagnosis of WAS.
- Hemophilia A/B: Normal platelet count, normal platelet size, factor deficiency on coagulation studies.
- Atopic dermatitis alone: No thrombocytopenia, normal immune studies.
- Other primary immunodeficiencies: Severe combined immunodeficiency (SCID: profound lymphopenia, absent T cells), X-linked agammaglobulinemia (XLA: no B cells, no immunoglobulin G), common variable immunodeficiency (CVID: normal/elevated MPV, normal platelets, adult onset).
- Bernard-Soulier syndrome: Large platelets (high MPV), GPIb/IX/V deficiency — opposite MPV to WAS.
Prenatal and Carrier Diagnosis
When the family mutation is known, prenatal diagnosis by chorionic villus sampling (CVS) or amniocentesis is available. Carrier testing of at-risk female relatives by WAS gene sequencing allows family planning and preparation for an affected pregnancy.
Treatment
Management of WAS is stratified by disease severity and the availability of a suitable hematopoietic stem cell transplant (HSCT) donor. For all patients, supportive measures begin immediately at diagnosis.
Supportive and Prophylactic Therapy
- IVIG (intravenous immunoglobulin): 400–600 mg/kg every 3–4 weeks. Reduces bacterial infection frequency by supplementing deficient immunoglobulin G and specific antibodies. Does not correct the cellular immune defect.
- Antimicrobial prophylaxis: Trimethoprim-sulfamethoxazole (TMP-SMX) for Pneumocystis pneumonia (PCP) prevention is standard for all patients with significant WASp deficiency. Antifungal prophylaxis (fluconazole) is added for patients with severe T-cell dysfunction.
- Vaccination: Live attenuated vaccines (MMR, live varicella) are contraindicated in classic WAS due to risk of vaccine-strain dissemination. Inactivated vaccines are given but elicit suboptimal responses. Post-exposure prophylaxis with varicella-zoster immune globulin is used after varicella exposure.
- Platelet transfusions: Reserved for active significant bleeding or pre-procedurally. Routine prophylactic transfusion is generally not used because of alloimmunization risk and the chronicity of the thrombocytopenia.
- Eczema management: Topical corticosteroids, emollients, calcineurin inhibitors; early treatment of superinfections. Systemic immunosuppression for severe eczema requires careful balancing against infection risk.
Hematopoietic Stem Cell Transplantation (HSCT) — Curative
HSCT has historically been the only proven curative therapy for WAS. It replaces the patient's defective hematopoietic system with donor-derived cells that carry a functional WAS gene, correcting all three arms of the classic triad — thrombocytopenia, immune deficiency, and (over time) eczema.
- Best outcomes: human leukocyte antigen-matched sibling donor, age under 5 years, before complications (autoimmunity, organ damage, malignancy) develop. Survival rates exceed 90% in this group.
- Matched unrelated donor (MUD) HSCT: Acceptable outcomes when no sibling donor is available, particularly in young children. Outcomes with 10/10 human leukocyte antigen-matched unrelated donors have improved significantly with modern conditioning and graft-versus-host disease (GVHD) prophylaxis.
- Haploidentical and cord-blood transplants: Used when no matched donor is available; higher GVHD and graft failure risk, but outcomes improving with T-cell depletion strategies.
- Timing: The European Society for Immunodeficiencies (ESID) and Inborn Errors Working Party guidelines recommend transplantation as early as feasible after diagnosis in classic WAS, ideally before 5 years of age.
Gene Therapy
Lentiviral vector-based gene therapy has emerged as a curative alternative for patients lacking a matched donor. The autologous approach — transducing the patient's own hematopoietic stem cells with a functional WAS cDNA under control of the endogenous WAS promoter — avoids GVHD entirely. The therapy, etuvetidigene autotemcel (research code OTL-103), was developed by a foundation, Fondazione Telethon, with the San Raffaele Telethon Institute for Gene Therapy (Milan). Trials of lentiviral gene therapy have shown:
- Durable WASp reconstitution in T cells, B cells, natural killer cells, and platelets beyond 5 years follow-up.
- Partial recovery of platelets in most patients, rather than normal counts. In a phase 1/2 trial of eight children, last-visit platelet counts were 20–50 × 109/L in one, 50–100 in five and over 100 in two, with no further platelet transfusions and no severe bleeding. In a separate long-term follow-up of eight patients (median 7.6 years), bleeding was significantly less frequent “despite only partial correction of the platelet compartment”.
- No evidence of insertional oncogenesis (cancer caused by where the vector lands in the DNA) with self-inactivating lentiviral vectors in the 27 people of the combined 2026 results.
- Combined 2026 results for etuvetidigene autotemcel (27 people, median age 2.6 years, median follow-up 5.7 years): overall survival 96% at both 1 and 5 years, with one death. Severe infections fell from 2.00 per person-year in the year before treatment to 0.15 between 6 and 18 months after it, and moderate or severe bleeding fell from 2.00 to 0.80 per person-year in the first year. The most common serious side effect was infection related to the central venous catheter.
- Regulatory approval: the United States approved etuvetidigene autotemcel in December 2025 for patients aged 6 months and older with a WAS gene mutation for whom stem cell transplant is appropriate and no suitable human leukocyte antigen-matched related donor is available; the European Union approved it for the same use in January 2026. An expanded-access program contributed 9 of the 27 people in the combined results.
Why Lentiviral Vectors Replaced the Earlier Ones
An earlier gene therapy trial in WAS used a gammaretroviral vector. It worked in 9 of 10 patients, with lasting correction of the protein and partial or complete resolution of immune deficiency, autoimmunity and bleeding, but 7 of the 10 developed acute leukemia because the vector had inserted near cancer-related genes such as LMO2. The authors concluded that this vector carries a substantial risk of leukemia. A 2026 review describes this as the reason the field moved to self-inactivating lentiviral vectors, and reports no cases of vector-related leukemia with them.
Splenectomy
Splenectomy significantly raises platelet counts (by removing the primary site of platelet destruction) but substantially increases the risk of overwhelming post-splenectomy sepsis with encapsulated organisms. In a patient who already has impaired polysaccharide antibody responses, this risk is amplified. A study of 173 patients with the milder form found that splenectomy increased the risk of severe infections. Splenectomy is generally avoided as definitive management and is not used before or instead of HSCT workup.
Prognosis
The prognosis of WAS has been transformed by HSCT and, more recently, gene therapy. The natural history — without curative treatment — is poor:
- Historically, median survival was approximately 15 years, with death most commonly from ICH in early childhood, severe infections in childhood and adolescence, or Epstein-Barr virus-driven lymphoma in the second or third decade.
- Autoimmune complications further worsen prognosis in WASp-null patients and may independently contribute to organ failure (renal, central nervous system (CNS) vasculitis).
With modern treatment:
- Matched sibling HSCT before age 5: Overall survival exceeds 90%. The classic triad is described as resolving — platelets normalize, immune competence is restored, eczema clears — and the risk of lymphoma as eliminated in successfully engrafted patients. An international study of 194 transplanted patients (1980–2009) reports overall survival of 84.0%, and 89.1% at 5 years for transplants since 2000; stable full donor chimerism (all blood-forming cells from the donor) was reached in 72.3% of those who survived at least a year, mixed chimerism was linked to incomplete lymphocyte recovery and autoimmunity after transplant, and myeloid donor chimerism under 50% to persistently low platelets. Malignancy after transplant is estimated at 3.3% in WAS. Quality of life approaches that of the general population.
- Matched unrelated donor HSCT: Outcomes approach sibling-matched HSCT in experienced centers with 10/10 human leukocyte antigen-matched donors and modern GVHD prophylaxis protocols.
- Gene therapy (etuvetidigene autotemcel): Combined results from phase 1–2 and phase 3 studies show 96% overall survival at 5 years (27 people) and durable correction beyond 5 years. Platelets recover partially in most patients. No lymphoma events after lentiviral gene therapy have been reported in WAS patients; this does not apply to the earlier gammaretroviral vector, after which 7 of 10 patients developed acute leukemia. Long-term survival data are still maturing.
- X-Linked Thrombocytopenia (XLT) — mild spectrum: Patients with partial WASp expression and the XLT phenotype can achieve near-normal lifespan with watchful waiting, IVIG, and avoidance of bleeding triggers. HSCT or gene therapy may still be appropriate in XLT patients with high bleeding burden or progressive disease. A study of 173 such patients found excellent long-term survival “but also a high probability of severe disease-related complications”, and a 2025 expert review states that most young patients with WAS should be offered a potentially curative approach at diagnosis, while older patients with a small subset of milder variants may be treated conservatively.
- Italian registry: 117 patients followed prospectively (92 with WAS, 25 with XLT; median follow-up 6 years). Overall survival at 25 years after HSCT was 75% in WAS, and over 80% since 2000; survival at 5 years was 100% with T-cell-depleted half-matched (haploidentical) HSCT or gene therapy. Among patients with WAS, hemolytic anemia affected 20% and vasculitis 9.3%. In the 25 patients with XLT, overall survival at 20 years was 83%.
Early diagnosis remains the most modifiable prognostic factor. Newborn screening programs using next-generation sequencing (NGS) panels — or screening for T-cell receptor excision circles (TREC) and kappa-deleting recombination excision circles (KREC) extended to WAS — have the potential to identify affected boys before their first serious complication, enabling early transplantation and optimal outcomes.
Key Research Papers
The following peer-reviewed publications represent foundational and landmark research in the understanding and treatment of Wiskott-Aldrich Syndrome:
- Derry JM, Ochs HD, Francke U. (1994). Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell. 78(4):635–644. — PubMed PMID: 8069912
- Symons M, Derry JM, Karlak B, et al. (1996). Wiskott-Aldrich syndrome protein, a novel effector for the GTPase CDC42Hs, is implicated in actin polymerization. Cell. 84(5):723–734. — PubMed PMID: 8625410
- Snapper SB, Rosen FS. (1999). The Wiskott-Aldrich syndrome protein (WASp): roles in signaling and cytoskeletal organization. Annual Review of Immunology. 17:905–929. — PubMed PMID: 10358777
- Filipovich AH, Stone JV, Tomany SC, et al. (2001). Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood. 97(6):1598–1603. — PubMed PMID: 11238097
- Imai K, Morio T, Zhu Y, et al. (2004). Clinical course of patients with WASP gene mutations. Blood. 103(2):456–464. — PubMed PMID: 12969986
- Aiuti A, Biasco L, Scaramuzza S, et al. (2013). Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science. 341(6148):1233151. — PubMed PMID: 23845947
- Moratto D, Giliani S, Bonfim C, et al. (2011). Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980–2009: an international collaborative study. Blood. 118(6):1675–1684. — PubMed PMID: 21659547
- Massaad MJ, Ramesh N, Geha RS. (2013). Wiskott-Aldrich syndrome: a comprehensive review. Annals of the New York Academy of Sciences. 1285:26–43. — PubMed PMID: 23527602
- Humblet-Baron S, Sather B, Anover S, et al. (2007). Wiskott-Aldrich syndrome protein is required for regulatory T cell homeostasis. Journal of Clinical Investigation. 117(2):407–418. — PubMed PMID: 17218989
- Braun CJ, Boztug K, Paruzynski A, et al. (2014). Gene therapy for Wiskott-Aldrich Syndrome — long-term efficacy and genotoxicity. Science Translational Medicine. 6(227):227ra33. — PubMed PMID: 24622513
- Puck JM, Candotti F. (2006). Lessons from the Wiskott-Aldrich syndrome. New England Journal of Medicine. 355(17):1759–1761. — PubMed PMID: 17065636
- Ochs HD, Thrasher AJ. (2006). The Wiskott-Aldrich syndrome. Journal of Allergy and Clinical Immunology. 117(4):725–738. — PubMed PMID: 16630926
- Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. (1994). A multiinstitutional survey of the Wiskott-Aldrich syndrome. Journal of Pediatrics. 125(6 Pt 1):876–885. — PubMed PMID: 7996359
- Albert MH, Bittner TC, Nonoyama S, et al. (2010). X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options. Blood. 115(16):3231–3238. — PubMed PMID: 20173115
- Buchbinder D, Nugent DJ, Fillipovich AH. (2014). Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments. Application of Clinical Genetics. 7:55–66. — PubMed PMID: 24817816
- Ferrua F, Cicalese MP, Galimberti S, et al. (2019). Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study. Lancet Haematology. 6(5):e239–e253. — PubMed PMID: 30981783
- Magnani A, Semeraro M, Adam F, et al. (2022). Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome. Nature Medicine. 28(1):71–80. — PubMed PMID: 35075289
- Vallée TC, Albert MH, Pai SY. (2025). How I treat Wiskott-Aldrich syndrome. Blood. 146(1):41–51. — PubMed PMID: 40209058
- Soresina A, Rondelli R, Notarangelo LD, et al. (2025). Long-term outcome in Wiskott-Aldrich syndrome and X-linked thrombocytopenia patients: an observational -prospective multi-center study of the Italian Primary Immune Deficiency Network (IPINET). EClinicalMedicine. 84:103271. — PubMed PMID: 40547444
- Blair HA. (2026). Etuvetidigene Autotemcel: First Approval. Molecular Diagnosis & Therapy. 30(3):539–543. — PubMed PMID: 41882319
- Ferrua F, Cenciarelli S, Giannelli S, et al. (2026). Etuvetidigene Autotemcel for the Treatment of Wiskott-Aldrich Syndrome. New England Journal of Medicine. 395(12):1193–1205. — PubMed PMID: 42777242
- Karimizadeh Z, Kalantari A, Behfar M, et al. (2026). From oncogenesis to approval: the lentiviral gene therapy revolution in Wiskott-Aldrich syndrome. Regenerative Medicine. 21(8-9):519–528. — PubMed PMID: 42856044
Connections
- Immunology
- Common Variable Immunodeficiency (CVID)
- Severe Combined Immunodeficiency (SCID)
- X-Linked Agammaglobulinemia (XLA)
- Immunoglobulin A Deficiency
- Chronic Granulomatous Disease
- Diseases — All Categories
- Thrombocytopenia — WAS causes a characteristic microthrombocytopenia (low platelet count with unusually small platelets).
- Genetic Susceptibility to Vaccine Adverse Reactions — combined immune and platelet considerations for vaccination